MELISSA DILORETO: Open Payments
NPI 1851670913 · NEWINGTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,010 in 39 payments from 18 companies in 2025. Trend: 2023 $1,014 · 2024 $850 · 2025 $1,010
Food & beverage: $910Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $119 |
| MILLICENT US INC | 5 | $112 |
| Sage Therapeutics, LLC | 4 | $97 |
| Exeltis, USA Inc. | 4 | $94 |
| Merck Sharp & Dohme LLC | 4 | $93 |
| Sumitomo Pharma America, Inc. | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Exact Sciences Corporation | 3 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| ABBVIE INC. | 1 | $33 |
Products named: ZURZUVAE, SLYND, GARDASIL 9, FEMLYV, REXULTI, Cologuard Collection Kit, MYFEMBREE, XIFAXAN.
Industry payments across CT — which companies pay providers there.
